~~<i id='7688537760'><strike id='7688537760'><tt id='7688537760'><pre id='7688537760'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：Wikipedia 2025-09-27 14:23:29 Page View：31

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Mass General Brigham physicians react to latest merger step
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

Study: Black kids more likely to die after surgery than white kids

AdobeEvenamongapparentlyhealthychildren,Blackpatientsarealmostthreeandahalftimesmorelikelytodiewithi

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Drug companies' payments and gifts affect physicians' prescribing

AdobeEachyear,abouthalfofallU.S.doctorsacceptmoneyorgiftsfromdruganddevicecompanies,totalingmorethan